Physician profile
Lorena S Walker
NPI 1871022137
$3,199.54
in general payments reported to CMS, 2019-2025
24 companies · $505 in 2025
The $505 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $806 · 2022: $516 · 2023: $421 · 2024: $952 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,858 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,857.65 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $514.79 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $487.27 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $427.22 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $229.54 | 2022-2024 | Evenity, Repatha, Otezla |
| Mayne Pharma Commercial LLC | $191.22 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.91 | 2021-2025 | Jardiance |
| Abbvie INC. | $128.95 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $125.80 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.99 | 2023 | |
| Axsome Therapeutics, INC. | $105.49 | 2025 | Auvelity |
| Biogen, INC. | $101.00 | 2025 | Zurzuvae |
| Glaxosmithkline, LLC. | $92.23 | 2022-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $92.17 | 2022-2024 | |
| Dexcom, INC. | $76.03 | 2023-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $66.21 | 2021-2024 | Freestyle Libre 3 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $54.32 | 2024-2025 | Korlym |
| Pfizer INC. | $50.19 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.53 | 2022 | |
| Janssen Pharmaceuticals, INC | $31.13 | 2024 | Spravato |
| Astellas Pharma US INC | $28.39 | 2024 | Veozah |
| Insulet Corporation | $26.02 | 2022 | |
| Hologic Sales and Service, LLC | $24.06 | 2024 | Aptima |
| Scilex Pharmaceuticals INC. | $21.82 | 2023 | Ztlido |
| Exact Sciences Corporation | $14.26 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorena Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.